Spastic Paraplegia 21 (Mast Syndrome) via the SPG21(ACP33) Gene
Summary and Pricing
Test Method
Exome Sequencing with CNV DetectionTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
8445 | SPG21 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if full gene Sanger sequencing is desired for STAT turnaround time, insurance, or other reasons, please see link below for Test Code, pricing, and turnaround time information.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).
Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).
The Sanger Sequencing method for this test is NY State approved.
For Sanger Sequencing click here.Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Spastic paraplegia 21 (SPG21), also known as Mast syndrome, is a complex form of hereditary spastic paraplegia (HSP). SPG21 has been described in several Old Order Amish and one Japanese family (Cross et al. 1967; Simpson et al. 2003; Ishiura et al. 2014). In addition to progressive weakness and spasticity in the lower extremity, SPG21 patients also manifest cognitive dysfunction, dementia, thinning of the corpus callosum, and white-matter abnormalities (Simpson et al. 2003; Ishiura et al. 2014). Some patients may also have cerebellar and extrapyramidal signs (Simpson et al 2003). Subtle symptoms may be present in childhood, but the main features occur in adulthood.
Genetics
SPG21 is inherited in an autosomal recessive (AR) manner. It is caused by pathogenic variants in ACP33, which encodes the protein designated “maspardin” (Mast syndrome, spastic paraplegia, autosomal recessive, with dementia) (Simpson et al. 2003). Maspardin has been shown to localize to endosomal/trans-Golgi transportation vesicles and may have functions in protein transport and sorting (Hanna et al. 2009). To date, one frameshift pathogenic variant (c.601dupA, p.Thr201Asnfs*13) has been found in Old Order Amish communities (Cross et al. 1967; Simpson et al. 2003) and one missense variant (c.322G>C, p.Ala108Pro) has been identified in a Japanese family (Ishiura et al. 2014).
Clinical Sensitivity - Sequencing with CNV PGxome
It is difficult to estimate the clinical sensitivity of this test due to the lack of large cohort studies. Pathogenic variants in SPG21 appear to be a rare cause of spastic paraplegia. The two reported pathogenic variants in SPG21 are detectable by sequencing.
Testing Strategy
This test provides full coverage of all coding exons of the SPG21 gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).
Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).
Indications for Test
Individuals with symptoms consistent with autosomal recessive HSP may consider this test. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in SPG21.
Individuals with symptoms consistent with autosomal recessive HSP may consider this test. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in SPG21.
Gene
Official Gene Symbol | OMIM ID |
---|---|
SPG21 | 608181 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Disease
Name | Inheritance | OMIM ID |
---|---|---|
Mast Syndrome | AR | 248900 |
Citations
- Cross H.E. et al. 1967. Archives of Neurology. 16: 1-13. PubMed ID: 6024251
- Hanna M.C. et al. 2009. Neurogenetics. 10: 217-78. PubMed ID: 19184135
- Ishiura H. et al. 2014. Journal of Human Genetics. 59: 163-72. PubMed ID: 24451228
- Simpson M.A. et al. 2003. American Journal of Human Genetics. 73: 1147-56. PubMed ID: 14564668
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
PGxome (Exome) Sequencing Panel
PGnome (Genome) Sequencing Panel
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.